01.09.26 -- Navigating The Challenges Of Cell Therapy Clinical Trials

Artificial intelligence (AI) is rapidly transforming clinical research, with innovative applications in key areas such as real-world evidence generation, regulatory submissions, and biomarker discovery.

Successful cell and gene therapy commercialization requires early, detailed manufacturer collaboration with health systems to ensure scalable operations and seamless patient access beyond the clinical trial.

Modern trials require precise insights to protect endpoints. Standardized imaging protocols ensure data consistency, reduce regulatory risk, and prevent the delays caused by last-minute amendments.

Psoriasis trials face recruitment, endpoint, regulatory, and operational challenges. Identifying common hurdles early helps sponsors streamline processes, avoid setbacks, and prevent costly delays.

Gain a greater understanding of how the right DCT solution, or combination of solutions, coupled with clear metrics and expert guidance on execution, can demonstrate tangible, quantitative ROI in clinical trials.

Biases, often hidden, can distort vendor selection decisions. Recognizing and addressing them across individuals and teams leads to more objective, aligned, and successful clinical trial outcomes.